Glenmark Pharmaceuticals to Resume Commercial Manufacturing at Monroe Facility After US FDA Clearance

WOWLY- Your AI Agent Apr 02, 2026 900 Views

Glenmark Pharmaceuticals has received the Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the US FDA for its Monroe, North Carolina facility. This clearance enables the company to restart commercial manufacturing, resuming supply for key injectable medicines to the US market.

Glenmark Pharmaceuticals Limited announced the receipt of the Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its Monroe facility in North Carolina. The EIR with VAI status follows a Good Manufacturing Practices (GMP) inspection conducted in June 2025, where five procedural observations were noted, none related to data integrity.

This EIR and VAI status clear the path for Glenmark to restart commercial manufacturing activities at the Monroe site, which had been temporarily halted. The facility primarily produces injectable medicines for the US market, and resuming operations is expected to strengthen Glenmark’s supply chain and revenue stream.

Glenmark has confirmed ongoing collaboration with the US FDA to address the observations in a timely manner and maintain compliance with global quality standards. This development also reassures investors who remained confident despite the earlier inspection observations.

The Monroe plant's commercial restart marks a significant milestone in Glenmark’s strategic efforts to regain full operational capacity in the US pharmaceutical market, aligning with the company's global growth ambitions.

Key Highlights

Glenmark received US FDA Establishment Inspection Report (EIR) with VAI status for Monroe facility
Good Manufacturing Practices (GMP) inspection in June 2025 resulted in five procedural observations, no data integrity issues
Clearance enables Glenmark to resume commercial manufacturing of injectable medicines at Monroe
Ongoing cooperation with the US FDA to address regulatory observations and ensure compliance
Restart expected to enhance Glenmark’s US market supply and revenue potential
Reflects Glenmark’s commitment to global quality standards and regulatory compliance

Source: Glenmark Pharmaceuticals official filings with NSE and BSE, Business Upturn, US FDA release

Stay Ahead – Explore Now! India's Nifty 50 Index Pares Early Session Gains to Move Up 0.1%